Patent: 10,413,539
✉ Email this page to a colleague
Summary for Patent: 10,413,539
Title: | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
Abstract: | The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. The ADC may be administered at a dosage of between 4 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, most preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the ADC can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the ADC is administered in combination with one or more other therapeutic agents, such as a PARP inhibitor, a microtubule inhibitor, a Bruton kinase inhibitor or a PI3K inhibitor. Most preferably, the ADC is of use for treating a Trop-2 expressing cancer, such as metastatic urothelial cancer. |
Inventor(s): | Govindan; Serengulam V. (Summit, NJ), Goldenberg; David M. (Mendham, NJ) |
Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
Application Number: | 15/820,708 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,413,539 |
Patent Claims: | see list of patent claims |
Details for Patent 10,413,539
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2032-12-13 |
Gilead Sciences, Inc. | TRODELVY | sacituzumab govitecan-hziy | For Injection | 761115 | 04/22/2020 | ⤷ Try a Trial | 2032-12-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |